Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

11.11.2019 | short review

Evidence-based follow-up in renal cell carcinoma

verfasst von: Karl Mayrhofer, MD, Dora Niedersüß-Beke, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Summary

The optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as well as surveillance after local ablative therapy. The recommendations and differences of major guidelines are outlined as well. A risk based approach is advocated taking into account both tumor and patient specific characteristics.
Vorheriger Artikel Evidence-based follow-up in lung cancer?
Nächster Artikel Importance of avoiding late cancer-directed therapy in terminally ill cancer patients
Literatur
1.
2.
Merrill SB, Sohl BS, Hamirani A, Lehman EB, Lehman KK, Kaag MG, et al. Capturing renal cell carcinoma recurrences when asymptomatic improves patient survival. Clin Genitourin Cancer. 2019;17(2):132–8.PubMedCrossRef
3.
Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol. 2018;36(1):11.e1–11.e6.CrossRef
4.
Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009;181(5):2044–51.PubMedCrossRef
5.
Beisland C, Guðbrandsdottir G, Reisæter LAR, Bostad L, Hjelle KM. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol. 2016;34(8):1087–99.PubMedCrossRef
6.
Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174(2):466–72. discussion 472; quiz 801.PubMedCrossRef
7.
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174(5):1759–63. discussion 1763.PubMedCrossRef
8.
Patard J‑J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the university of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.PubMedCrossRef
9.
Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7.PubMedCrossRef
10.
Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78(5):1101–6.PubMedCrossRef
11.
Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol. 2013;64(3):472–7.PubMedCrossRef
12.
Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, et al. Evaluation of the national comprehensive cancer network and American urological association renal cell carcinoma surveillance guidelines. J Clin Oncol. 2014;32(36):4059–65.PubMedPubMedCentralCrossRef
13.
Stewart-Merrill SB, Thompson RH, Boorjian SA, Psutka SP, Lohse CM, Cheville JC, et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol. 2015;33(35):4151–7.PubMedCrossRef
14.
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European Multicentre database (RECUR). Eur Urol. 2019;75(2):261–4.PubMedCrossRef
15.
Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, et al. The usefulness of chest X‑rays for T1a renal cell carcinoma surveillance. J Urol. 2016;196(2):321–6.PubMedCrossRef
16.
Chow AK, Kahan AN, Hwang T, Coogan CL, Latchamsetty KC. Should we separate the pulmonary surveillance protocol for postsurgical T1a and T1b renal cell carcinoma? A multicenter database analysis. Urology. 2018;122:127–32.PubMedCrossRef
17.
Doornweerd BHJ, de Jong IJ, Bergman LM, Ananias HJK. Chest X‑ray in the follow-up of renal cell carcinoma. World J Urol. 2014;32(4):1015–9.PubMed
18.
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand J Urol. 2019;53(1):14–20.PubMedCrossRef
19.
Platzek I, Zastrow S, Deppe P‑E, Grimm M‑O, Wirth M, Laniado M, et al. Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiol. 2010;51(5):581–9.PubMedCrossRef
20.
Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38(2):156–63.PubMedCrossRef
21.
Gofrit ON, Orevi M. Diagnostic challenges of kidney cancer: a systematic review of the role of positron emission tomography-computerized tomography. J Urol. 2016;196(3):648–57.PubMedCrossRef
22.
23.
Shvarts O, Lam JS, Kim HL, Han K, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004;172(3):867–70.PubMedCrossRef
24.
Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol. 2008;179(4):1227–33. discussion 1233–1234.PubMedCrossRef
25.
Iannuccilli J, Grand D, Dupuy D, Mayo-Smith W. Percutaneous ablation for small renal masses-imaging follow-up. Semin intervent Radiol. 2014;31(1):50–63.PubMedPubMedCentralCrossRef
26.
Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176(5):1973–7.PubMedCrossRef
27.
Patel U, Sokhi H. Imaging in the follow-up of renal cell carcinoma. AJR Am J Roentgenol. 2012;198(6):1266–76.PubMedCrossRef
28.
Thumar AB, Trabulsi EJ, Lallas CD, Brown DB. Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol. 2010;21(8 Suppl):S233–41.PubMedCrossRef
29.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.PubMedCrossRef
30.
Motzer RJ, Jonasch E, Agarwal N, National Comprehensive Cancer Network. Kidney Cancer. 2019;64. Referenced with permission from the NCCN Guidelines® for Kidney Cancer V.2.2020 © National Comprehensive Cancer Network. 2019. www.​NCCN.​org. Accessed 28 June 2019.
31.
Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013;190:407–16.PubMedCrossRef
32.
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–20.PubMedCrossRef
33.
Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006;8(1):1–7.PubMedPubMedCentral
34.
Williamson TJ, Pearson JR, Ischia J, Bolton DM, Lawrentschuk N. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016;117(4):555–62.PubMedCrossRef
Metadaten
Titel
Evidence-based follow-up in renal cell carcinoma
verfasst von
Karl Mayrhofer, MD
Dora Niedersüß-Beke, MD, MBA
Publikationsdatum
11.11.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00540-9

Weitere Artikel der Ausgabe 1/2020

While I breathe, I hope. Principles of palliative care in chronic breathlessness and advanced lung diseases

  • Open Access
  • short review

CAR-T cells in multiple myeloma: current status

  • Open Access
  • short review

Complete remission of disseminated Langerhans cell sarcoma after stem cell transplantation

  • Open Access
  • case report

CAR T-cell therapy in diffuse large B-cell lymphoma

  • Open Access
  • short review

Evidence-based follow-up in patients with Hodgkin’s lymphoma and aggressive B-cell non-Hodgkin’s lymphoma

  • review

AML—is it time to drive a CAR(-T)?

  • Open Access
  • short review